AcuCort (”AcuCort” eller ”Bolaget”) meddelade den 19 december år 2024 att Bolaget har lämnat in en I...
The divestment price estimate of Enersense’s wind power portfolio (2.
Redeye endorses the news that BioArctic has signed a licensing agreement with BMS regarding BioArcti...
New defence order from BAE Systems worth SEK 53m Additional order from Denmark also expected near-te...
Mendus has reported positive top-line data for its Phase I ALISON trial, which is evaluating lead of...
I torsdags aviserade industrikoncernen AGES Industri pågående diskussioner kring en eventuell fusion...
SEK 185m order from Swedish Space Corporation on Ovzon-3 The full value will be paid in January 2025...
Redeye leaves a comment following Lipum’s announcement of a grant from Eurostars.
On December 17th, STENOCARE announced that the company has received approval for a new product in De...
Redeye comments on the successful directed share issue of NOK100m and EUR1m primary bid offering.
SRV’s 2025 will still be driven by non-residential volumes while we expect that the residential pick...
Redeye initiates coverage of Safello, a Swedish cryptocurrency brokerage founded in 2013 that has ce...
Redeye is positive to the news regarding the support from a new law in New York state for insurance ...
Mendus continues to make headway with its lead programme assessing cancer vaccine vididencel as a po...
Today, Medivir announced its application to start a phase II study in liver cancer was approved by t...
Redeye comments on Lipigon's change of CEOs.
Redeye sees encouraging news from Dignitana supporting insurance coverage from private health insure...
Pharma Equity Group (“PEG” or “the Company”) announced on Friday, December the 13th, the board of di...
Tethys Oil har under hösten fått ett bud på 58,70 kr per aktie som ligger i princip mitt i intervall...
Redeye leaves a comment following Magle’s recent announcement of a directed share issue of approxima...
